Apollo Gleneagles Cancer Hospital
Day | Time |
---|---|
Sunday | Closed |
Monday | 09:00 AM - 05:00 PM |
Tuesday | 09:00 AM - 05:00 PM |
Wednesday | 09:00 AM - 05:00 PM |
Thursday | 09:00 AM - 05:00 PM |
Friday | 09:00 AM - 05:00 PM |
Saturday | 09:00 AM - 05:00 PM |
Consultation Fee
₹800
Hematologic Oncologist
4.5
Social Profiles:
Bone Marrow Transplant
Hormone Therapy For Breast Cancer
Stem Cell Transplantation
Hemato Oncology
Medical Oncology
Oncology
Cancer Screening
cancer patient counseling
Angiosarcoma Treatment
Breast Cancer Screening
Gynecological Cancer Treatment
Brain cancer Treatment
Breast Lump Treatment
Lung Cancer
Head and neck cancer
Dr. Indranil Ghosh is a doctor who helps people with cancer. He has a lot of experience and has been working for 20 years. Dr. Ghosh studied at top medical schools in India and has special training in treating cancer. He is known as a Hematologic Oncologist.
Dr. Ghosh has worked at different hospitals like AIIMS, Tata Medical Center, and Apollo Gleneagles Hospitals. He is now a Consultant at Apollo Gleneagles Hospitals in Kolkata. Dr. Ghosh is very skilled in Bone Marrow Transplant, Hormone Therapy for Breast Cancer, and Stem Cell Transplantation.
Patients like Dr. Ghosh because he talks to them in a way they can understand. He is very caring and listens to their concerns. He always stays updated on the latest research to give the best treatment to his patients.
Dr. Ghosh works well with other doctors and medical staff. He shares his knowledge and learns from them too. This teamwork helps patients get the best care possible.
Dr. Ghosh has won many awards for his hard work and dedication. He has helped many people get better from cancer. His patients trust him because he is kind, knowledgeable, and always there to help.
Lastly, Dr. Indranil Ghosh is a skilled and caring doctor who specializes in treating cancer. He has helped many patients and continues to learn and grow to provide the best care possible. Patients trust him because of his expertise, compassion, and dedication to their well-being.
MD - Pediatrics - All India Institute of Medical Sciences, New Delhi, 2007
MBBS - Calcutta University, 2002
DM - Medical Oncology - All India Institute of Medical Sciences, New Delhi, 2010
American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
2007 - 2010 Senior Registrar at AIIMS
2011 - 2011 Consultant at AMRI
2011 - 2013 Consultant at Tata Medical Center
2013 - 2017 Consultant at Apollo Gleneagles Hospitals
60348 West Bengal Medical Council, 2004
Publisher: Journal of Oncology Pharmacy Practice
Year: 2025
About 1% to 5% of cases of non-small cell lung cancer (NSCLC) have been found to have a BRAF mutation. There is no phase III data, despite the fact that numerous phase II and retrospective studies have demonstrated the efficacy of single agent BRAF inhibition and combination BRAF/MEK inhibition in patient groups that have received treatment and those who have not. Our goal in this systematic review was to provide an overview of the available evidence in this context.
Publisher: Medical Oncology
Year: 2012
Objective of the present study was to describe the profile of infections in febrile neutropenia (FN) in acute leukemia and hematopoietic stem cell transplant (HSCT) with emphasis on response to therapy and outcome. In a prospective, observational single-institutional study, consecutive episodes of high-risk FN were enrolled over a 1½-year period. Uniform antibiotic policy and response criteria were used. Of the 200 episodes enrolled, acute leukemia induction comprised 40.5%, consolidation with high-dose cytarabine 22.5%, HSCT 29% (auto-HSCT 84%), and others 8% of the episodes, respectively. Microbiologically documented infections comprised 30% episodes, while bacteremia was documented in 26% episodes. Gram-negative isolates were more common (55.7%). Cefoperazone–sulbactam had the highest in vitro efficacy against Gram-negative rods. Carbapenem resistance was most prevalent among Acinetobacter spp. (80%) and Pseudomonas aeruginosa (50%). All Gram-positive cocci other than enterococci were susceptible to vancomycin, while 2/8 enterococci were resistant to it. Cefoperazone–sulbactam and amikacin were used as first-line antibiotics. Overall mortality was 8%. On multivariate analysis, mortality was associated with a nadir leukocyte count < 200/μl and an abnormal chest radiograph. Among high-risk FN patients, inspite of a high-level of resistance to antibiotics, a frontline regime containing cefoperazone–sulbactam could restrict the use of imipenem and resulted in an acceptable mortality of 8%.
Publisher: Nuclear Medicine Review
Year: 2021
Double primary lung cancer (DPLC) is a rare occurrence of primaries of different histologies or the same histology in different lobes in absence of advanced nodal or distant metastasis. It could be synchronous or metachronous. They are frequently misdiagnosed as metastasis or recurrence. This study presents the staging [¹⁸F]Fluorodeoxyglucose positron emission tomography-computed tomography findings in a case of a 74-year-old man with DPLC of different histologies.
Dr. Indranil Ghosh is a compassionate Hematologic Oncologist who truly cares about his patients' well-being. He took the time to explain my treatment plan in detail and answered all my questions patiently.
I am grateful to Dr. Indranil Ghosh for his expertise in Hematologic Oncology. His dedication to providing personalized care and his positive attitude made me feel confident throughout my treatment journey.
Dr. Indranil Ghosh is a skilled Hematologic Oncologist who goes above and beyond for his patients. His professionalism and knowledge in the field are truly commendable.
I highly recommend Dr. Indranil Ghosh for anyone seeking Hematologic Oncology care. His approachable demeanor and genuine concern for his patients' well-being set him apart.
Dr. Indranil Ghosh is an exceptional Hematologic Oncologist who provides top-notch care with a personalized touch. His expertise and compassion make him a standout in his field.
I am extremely satisfied with the care I received from Dr. Indranil Ghosh, a Hematologic Oncologist par excellence. His attention to detail and willingness to listen made all the difference in my treatment.
Dr. Indranil Ghosh is a brilliant Hematologic Oncologist who is dedicated to his patients' well-being. His thorough approach and clear communication instilled confidence in me throughout my treatment.
I am thankful for the exceptional care provided by Dr. Indranil Ghosh, a Hematologic Oncologist with a heart of gold. His expertise and empathy made my treatment journey much smoother.
Dr. Indranil Ghosh is a true professional in the field of Hematologic Oncology. His commitment to his patients' health and well-being is truly commendable, and I am grateful for his care.